New approaches in graft versus host disease (GvHD) management
Abstract Graft versus host disease (GVHD) remains the major cause of morbidity and nonrelapse mortality (NRM) after allogeneic hematopoietic stem cell transplantation (HSCT). Although the understanding of its biological basis is continuously improving and candidate target pathways therefore increasingly emerge, severe, steroid-refractory GVHD remains an unsolved issue with a rather poor prognosis in clinical practice thus far. With the exception of the Janus kinase (JAK) 1/2 inhibitor, ruxolitinib, which has demonstrated considerable effectiveness in steroid-refractory GVHD in a multicenter survey, ...
Source: Memo - Magazine of European Medical Oncology - March 8, 2016 Category: Cancer & Oncology Source Type: research

Intensive care for cancer patients
Abstract Every sixth to eighth European intensive care unit patient suffers from an underlying malignant disease. A large proportion of these patients present with cancer-related complications. This review explains why the prognosis of critically ill cancer patients has improved substantially over the last decades and which risk factors are of prognostic importance. Furthermore, the main reasons for intensive care unit admission – acute respiratory failure and septic complications – are discussed with regard to diagnostic and therapeutic specifics. In addition, we discuss potential intensive care ...
Source: Memo - Magazine of European Medical Oncology - March 8, 2016 Category: Cancer & Oncology Source Type: research

Adjuvant medical treatment for breast cancer in elderly and old women
Abstract The probability of developing breast cancer increases with age. Therefore, more than 50 % of women with breast cancer are older than 65 years at the time of diagnosis. However, elderly patients are often undertreated and clinical trials for elderly patients in the adjuvant setting are lacking. Elderly patients who are otherwise fit should receive the standard treatment regimen independent of age. Endocrine therapy should not be withheld from patients by age alone. Thus, there are more adverse events in the elderly population. The decision on adjuvant chemotherapy should be ma...
Source: Memo - Magazine of European Medical Oncology - March 8, 2016 Category: Cancer & Oncology Source Type: research

memo—new frontiers to be reached
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - March 8, 2016 Category: Cancer & Oncology Source Type: research

Treatment of elderly patients with advanced urological cancer
Abstract The treatment of advanced urological cancers has evolved tremendously over the last decade. As the incidence of these cancers is increasing with age, uro-oncologists are increasingly faced with the challenge of choosing optimal therapeutic strategies for elderly patients. Comorbidities interfering with cancer treatment can be identified by geriatric assessment tools that should be applied in elderly cancer patients before starting therapy. Using these tools competing risks of morbidity and mortality can be evaluated. We provide a review on evidence based treatments in elderly prostate, bladder and renal c...
Source: Memo - Magazine of European Medical Oncology - March 7, 2016 Category: Cancer & Oncology Source Type: research

Proceedings of the Annual Meeting of the
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - March 1, 2016 Category: Cancer & Oncology Source Type: research

Treatment of elderly and very old patients with AML
Abstract Acute Myeloid Leukemia (AML) is a genetically heterogeneous malignant disease mainly occurring in elderly patients. The prognosis of patients over 60 years of age, which represent the majority of patients, which are diagnosed, remains poor. The main reasons for the poor outcome are the in-creasing number of comorbidities, organ impairments and nevertheless the unfavorable genetic features, pre-existing myelodysplastic changes and rising multi-drug resistance. It is also more likely that older and frail patients are not included into clinical trials and treatment decisions have to be made on general assump...
Source: Memo - Magazine of European Medical Oncology - February 29, 2016 Category: Cancer & Oncology Source Type: research

Treatment of elderly patients with melanoma
Abstract Treatment options for melanoma patients, both young and old, were extremely limited until recently. Elderly patients faced a particular challenge due to less aggressive surgical management, poor tolerance of available therapies, aggressive biologic behaviors, and rapid tumor progression. Over the past several years, however, a number of remarkably active immune and targeted agents have been developed. These agents are generally well tolerated and present numerous effective therapeutic options for elderly patients with advanced melanoma. In this manuscript, we discuss the distinct clinical and genetic aspe...
Source: Memo - Magazine of European Medical Oncology - February 8, 2016 Category: Cancer & Oncology Source Type: research

Parapharyngeal malignant peripheral nerve sheath tumor: a case report and review of the literature
We report on a patient who presented to the ear, nose, and throat (ENT) clinic with swelling on the right side of the neck. Imaging studies revealed a large expansive heterogeneous process encroaching on the parapharyngeal region. Postintravenous contrast administration revealed an ovoid mass with moderate enhancement without affecting the parotid gland. The patient underwent full tumor resection, and a biopsy confirmed the presence of a malignant peripheral nerve sheath tumor (MPNST). In addition, as part of the treatment the patient received radiation therapy and is currently disease-free with no visible complications or...
Source: Memo - Magazine of European Medical Oncology - February 8, 2016 Category: Cancer & Oncology Source Type: research

Open Access publizieren in „memo – magazine of european medical oncology“
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - February 4, 2016 Category: Cancer & Oncology Source Type: research

Treatment of elderly patients with diffuse large B-cell lymphoma
Abstract With the implementation of rituximab, tremendous progress has been achieved in the treatment of diffuse large B-cell lymphoma (DLBCL). Nevertheless, the majority of patients with DLBCL are over the age of 65 years and the management of these patients is often suboptimal. Standard chemo-immunotherapy with curative approach should be appropriate for all elderly patients who can tolerate it. Therefore, a careful evaluation of each patient is mandatory prior to treatment allocation. R- CHOP regimen (rituximab, cyclophosphamide doxorubicin, vincristine, prednisolone) remains the standard of care, but special a...
Source: Memo - Magazine of European Medical Oncology - February 1, 2016 Category: Cancer & Oncology Source Type: research

Never too old to treat cancer?
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - January 25, 2016 Category: Cancer & Oncology Source Type: research

Adipositasepidemiologie in Österreich
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - December 15, 2015 Category: Cancer & Oncology Source Type: research

Malignant pleural effusion: pathogenesis, diagnosis, and management
Abstract Pleural effusion is common in various diseases and especially malignant effusions can have rapid onset symptoms such as dyspnea, chest pain, and coughing. The diagnosis and the treatment approaches require several pleural techniques and knowledge about concomitant disease. In exudative effusions accompanying inflammatory reactions in pneumonia are the most common reasons. Malignant effusions are typically seen in lung and breast cancer patients. The differential diagnosis has to always include malignant pleural mesothelioma. The therapeutic approach is dependent on staging, symptoms, and prognosis of the ...
Source: Memo - Magazine of European Medical Oncology - December 11, 2015 Category: Cancer & Oncology Source Type: research

TruSight Cancer Sequencing Panel reveals pharmacogenetic variants associated with sensitivity to chemotherapy in lung cancer
We report reference SNP (rs)1042522 (TP53), rs2228001 (XPC), rs2227983 (EGFR), rs1799793, and rs13181 (ERCC2) single nucleotide polymorphism variants which have been detected in our patients in homozygous and/or heterozygous state. Therefore, we give important information to confirm the role of those polymorphisms in tumor resistance and recurrence after chemotherapy treatment. The results reveal that TruSight Cancer Panel could be a useful clinical tool for determining pharmacogenetic variants associated with the effect of chemotherapy. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - December 8, 2015 Category: Cancer & Oncology Source Type: research

8-year-sustained response in a patient with isolated del(5q) myelodysplastic syndrome undergoing continuous treatment with lenalidomide: a case report
We report a case of an 84-year-old patient with International Prognostic Scoring System (IPSS)-defined low-risk MDS with isolated del(5q), who has received continuous lenalidomide treatment for the past 8 years and whose treatment is ongoing. Grade 3 or 4 neutropenia and thrombocytopenia, which occurred in approximately 60 % of the patients during the first weeks of treatment, did not occur in our patient. Also, there were no thromboembolic events or a progression to acute myeloid leukemia. This case highlights the role of lenalidomide in modifying the course of low-risk del(5q) MDS in long-term responders by induci...
Source: Memo - Magazine of European Medical Oncology - December 8, 2015 Category: Cancer & Oncology Source Type: research

Erratum to: A review on biomolecular basis of the role of psychological stress in the development and progression of cancer
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - December 8, 2015 Category: Cancer & Oncology Source Type: research

Report from the 18th ECCO- 40th ESMO European Cancer Congress, Vienna 25th–29th September 2015
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - December 1, 2015 Category: Cancer & Oncology Source Type: research

Giant Merkel cell carcinoma of the face, immediate results after radiation therapy: a case report and review of the literature
We report on a patient who presented to the ear, nose, and throat (ENT) clinic with a large lesion on the left side of the face. Imaging studies revealed a large heterogeneous expansive mass in the left gonial region infiltrating the skin. The lesion was highly enhanced following intravenous contrast injection (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - December 1, 2015 Category: Cancer & Oncology Source Type: research

ASCO 2015: highlights in colorectal cancer
Abstract Two “first-in” studies of colorectal liver metastases were highlighted at the 2015 ASCO Annual Meeting: the first prospective randomized trial to evaluate radiofrequency ablation plus chemotherapy [J Clin Oncol 33] and the first large randomized phase III trial to study liver-directed selective internal radiation therapy [J Clin Oncol 33]. Radiofrequency ablation plus chemotherapy appeared to have clear benefit in this setting, whereas the results for selective internal radiotherapy in first-line therapy are currently less conclusive. Colorectal tumors that lacked the ability to repair DNA&mda...
Source: Memo - Magazine of European Medical Oncology - December 1, 2015 Category: Cancer & Oncology Source Type: research

Exosomes as novel biomarkers in anticancer therapy
Abstract Extracellular vesicles, particularly small exosomes with a size between 40 and 120 nm, contain complex information. Most importantly, exosomes may transfer this information to recipient cells and alter their cellular programme. If decoded, this information reveals ongoing malignant processes within the organism such as drug resistance or metastases formation (functional biomarker). As this information is composed of RNA, DNA fragments, proteins and metabolites, these molecules may also serve as molecular biomarker. Exosomes are generated from parental cells, frequently under disease conditions. Thus,...
Source: Memo - Magazine of European Medical Oncology - December 1, 2015 Category: Cancer & Oncology Source Type: research

Biomarkers—hope and hype
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - December 1, 2015 Category: Cancer & Oncology Source Type: research

Obituary for Dr. Ferdinand Ploner
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - November 17, 2015 Category: Cancer & Oncology Source Type: research

American Society of Clinical Oncology annual meeting 2015
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - November 12, 2015 Category: Cancer & Oncology Source Type: research

Clinical relevance of circulating tumor cells in cancer patients
Abstract Historically disseminated tumor cells in solid cancers were detected by immunohistochemistry of bone marrow aspirates. Blood samples are more easily and frequently accessible and are therefore employed to detect circulating tumor cells (CTCs), a procedure termed “liquid biopsy”. CTCs are shed from tumors and a fraction of these cells is capable of establishing distal lesions. Since patients die from metastatic disease, CTCs hold potential to have prognostic significance and to indicate the success or failure of therapeutic interventions. With few exceptions, CTCs are rare cells against a large...
Source: Memo - Magazine of European Medical Oncology - November 4, 2015 Category: Cancer & Oncology Source Type: research

ASCO 2015: Highlights in breast cancer
Abstract Several important studies were presented at the 2015 ASCO Annual Meeting in the field of breast cancer. Austrian Breast and Colorectal Study Group trial 18 again indicated the importance of bone health in postmenopausal women receiving endocrine therapy and showed that denosumab, a monoclonal antibody targeting the RANK ligand, was highly active in the reduction of fracture rates in this population. In the metastatic setting, addition of palbociclib to fulvestrant nearly tripled progression-free survival in pretreated women with luminal breast cancer as shown in the randomized phase III PALOMA-3 trial. In...
Source: Memo - Magazine of European Medical Oncology - November 3, 2015 Category: Cancer & Oncology Source Type: research

ASCO 2015 special issue
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - November 1, 2015 Category: Cancer & Oncology Source Type: research

Thermoablation: a new treatment option to replace surgical intervention?
Abstract Local tumor ablation either by high or low temperatures is an ever increasing local therapeutic procedure in the interdisciplinary armamentarium of anticancer therapy. As cryoablation (local cancer tissue destruction by low temperature) is technically demanding, rather expansive and thus has gained low acceptance and low distribution in interventional oncologic radiology, this paper will focus on the state-of-the-art of local tumor cell destruction by high temperatures and electroporation: radiofrequency ablation (RFA), microwave ablation (MWA), and irreversible electroporation (IRE). (Source: Memo - Maga...
Source: Memo - Magazine of European Medical Oncology - October 14, 2015 Category: Cancer & Oncology Source Type: research

Soft tissue sarcomas & GIST Insights into subtype-specific therapy concepts: Highlights from ASCO meeting 2015
Abstract Sarcomas are a rare and heterogeneous group of mesenchymal malignancies that have historically been challenging in diagnosis and treatment. In soft tissue sarcomas (STS), the recognition of different histological subtypes has made a dramatic conceptual change leading to histotype-driven targeted therapies. In gastrointestinal stromal tumors (GIST), the most important advance in the past decade was the demonstration that tyrosine kinase inhibitors (TKIs) can durably control disease and lead to remarkable treatment responses. The advent of TKIs has unquestionably changed the overall survival of patients wit...
Source: Memo - Magazine of European Medical Oncology - September 24, 2015 Category: Cancer & Oncology Source Type: research

ASCO update 2015: lung cancer
Abstract The aim of this short review is to summarize the randomized phase III trials with the highest impact on daily clinical practice relating to the field of lung cancer presented at the ASCO annual meeting 2015. With the presentation of data from the CheckMate 017 and 057 trials, comparing the anti-PD1-antibody nivolumab to standard docetaxel in the second-line treatment of patients with metastatic squamous and non-squamous non-small-cell lung cancer, immunotherapeutic strategies have finally arrived in daily routine, as the antibody treatment in these trials led to superior results concerning survival, toxic...
Source: Memo - Magazine of European Medical Oncology - September 23, 2015 Category: Cancer & Oncology Source Type: research

ASH 2014: novel strategies in the management of classical Hodgkin’s lymphoma
Abstract This review discusses promising new approaches in the management of classical Hodgkin’s lymphoma that have been recently presented at the annual ASH meeting. Novel insights regarding risk-adapted, tailored therapy as well as improved treatment strategies in relapsed/refractory disease have been presented. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 16, 2015 Category: Cancer & Oncology Source Type: research

“Just because your doctor has a name for your condition doesn’t mean he knows what it is.” Bertrand Russell
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 15, 2015 Category: Cancer & Oncology Source Type: research

Prognostic factors and their correlation with staging in patients with multiple myeloma: a single centre study in North India
Abstract Background Multiple myeloma is a neoplastic disorder characterised by proliferation of a single clone of plasma cells leading to varied clinical presentations. Various clinical and laboratory parameters have been established as prognostic factors but their correlation with staging systems has been sparingly studied in Indian population. Methods A retrospective study was done over a period of 30 months at a tertiary care centre including 33 patients of multiple myeloma. Physical examination, radiological investigations and routine laboratory inve...
Source: Memo - Magazine of European Medical Oncology - September 14, 2015 Category: Cancer & Oncology Source Type: research

Changing treatment paradigms in lymphoma: new targets and new drugs
Abstract The knowledge about biological mechanisms contributing to lymphomagenesis represents the basis for targeted therapies in lymphoproliferative disorders. Herein, we provide a short overview about the novel drugs targeting B-cell non-Hodgkin lymphomas, with a focus on diffuse large B-cell lymphomas. Due to the plethora of new drugs, we present some of the most important new drug developments in lymphoma treatment, namely humanized monoclonal antibodies, monoclonal antibody conjugates, immunomodulatory agents, and tyrosine kinase inhibitors. The use of these agents alone or in combination with chemotherapy sh...
Source: Memo - Magazine of European Medical Oncology - September 14, 2015 Category: Cancer & Oncology Source Type: research

Gastric and esophageal cancer: Post ASCO 2015
Abstract Immunologic tumor therapy was the leading theme of this year’s ASCO. In this context first results for check point inhibitors active in esophageal and gastric cancer were presented. Phase III trials involving c-met inhibitors however were not successful. First phase II results with regorafenib emphasize a potential role for TKI’s in gastric cancer. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 8, 2015 Category: Cancer & Oncology Source Type: research

ASH 2014 highlights: new therapeutic concepts for T cell lymphomas
Abstract The Annual Meeting of the American Society of Hematology (ASH) 2014 has highlighted a number of spectacular advances of the past couple of years for T cell lymphomas. These lymphomas are probably the most challenging of all types of hematologic malignancies: First, patients usually present in a very ill condition and in a very advanced stage of disease; second, they do not respond well to chemotherapy; and third, T cell lymphomas are rare diseases. They account for only 15 % of all cases of non-Hodgkin lymphomas and with more than 15 subtypes any subtype is very rare [1]. Therefore, it requires joi...
Source: Memo - Magazine of European Medical Oncology - September 8, 2015 Category: Cancer & Oncology Source Type: research

Highlights of the American Society of Hematology Meeting 2014: Hemostaseology
Abstract In patients suffering from venous thromboembolism, the subsequent anticoagulation treatment significantly reduces the risk of recurrence of further thromboembolic events. However, all available treatment options put the patients at risk of potential life-threatening bleeding complications. Consequently, during the 56th Annual Meeting 2014 of the American Society of Hematology in San Francisco researchers focused on optimizing the use of the current available anticoagulants. Therefore, in the Choosing Wisely® campaign the expert committee recommended to treat patients suffering from their first venous ...
Source: Memo - Magazine of European Medical Oncology - September 8, 2015 Category: Cancer & Oncology Source Type: research

CESAR-Jahrestagung 2015/ Annual Meeting 2015
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - August 25, 2015 Category: Cancer & Oncology Source Type: research

Chronic lymphocytic leukemia: ASH update 2014
Abstract At the annual meeting of the American Society of Hematology 2014 in San Francisco, a variety of important clinical trials covering topics like first-line immunochemotherapy, maintenance therapy with monoclonal antibodies as well as confirmatory data of novel therapies such as B-cell receptor or BCL2 inhibitors were presented. In view of these data new clinical standards have been set up and validated, respectively. Taken together, the data presented underscores the importance of immunochemotherapy despite the upcoming era of tyrosine kinase inhibitor treatment in chronic lymphocytic leukemia (CLL) as a st...
Source: Memo - Magazine of European Medical Oncology - August 21, 2015 Category: Cancer & Oncology Source Type: research

A 59-year-old patient with somatic type malignancy as a relapse of testicular tumor after 28 years
Abstract A 59-year-old patient presented in the outpatient clinic because of an increasing mass in his right buttock. He has a history of a testicular tumor 28 years ago, with increased tumor markers (Human Choriongonadotropin (β-HCG) value 4.9 and Alpha-1 Fetoprotein (AFP) 218 ng/ml). (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - August 19, 2015 Category: Cancer & Oncology Source Type: research

Aggressive lymphoma: news on ASH 2014
This article reviews the most important news at American Society of Hematology (ASH) 2014 for the clinician. A validated risk model for central nervous system (CNS) relapse after rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) defined a low, intermediate, and a high risk group. The latter with a CNS-relapse risk of 12 %. Interim positron emission tomography (PET) imaging and different treatment strategies for positive disease were highly prognostic for an unfavorable prognosis. However, the salvage strategies for these patients were not successful. The role of radiotherapy was clarifie...
Source: Memo - Magazine of European Medical Oncology - July 30, 2015 Category: Cancer & Oncology Source Type: research

ASH 2014 update: Myelodysplastic syndromes and acute myeloid leukemia
Abstract Treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), especially in older patients with comorbidities, is still a challenge and awaits further improvement regarding outcomes. Therefore data presented on this topic at the 2014 American Society of Hematology (ASH) meeting are of importance and need to be discussed in the context of current and future clinical practice. This review covers studies for AML and MDS (excluding transplantation) reported at the last ASH meeting that demonstrate progress in this field and suggest a way forward from chemotherapy to biological treatment appro...
Source: Memo - Magazine of European Medical Oncology - July 28, 2015 Category: Cancer & Oncology Source Type: research

Notes on breast cancer prevention and screening
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - July 2, 2015 Category: Cancer & Oncology Source Type: research

Indolent lymphoma at ASH 2014: new kids on the block (iDrugs)
Abstract Recent clinical data presented at the annual meeting of the American Society of Hematology support the potential use of chemotherapy-free combinations in first-line treatment of follicular lymphoma. Rituximab maintenance seems to be very useful after autologous stem cell transplantation in younger patients with mantle cell lymphoma (MCL). In elderly MCL patients the integration of bortezomib in frontline treatment strategies is very promising. Moreover, new therapeutic agents such as ibrutinib and idelalisib are tested successfully in clinical trials in relapsed indolent lymphoma. (Source: Memo - Magazine...
Source: Memo - Magazine of European Medical Oncology - July 2, 2015 Category: Cancer & Oncology Source Type: research

Clinical utility of circulating tumor DNA in human cancers
Abstract The use of circulating tumor DNA (ctDNA) as a prognostic and/or predictive biomarker has been proven in numerous studies. Recent technical advancements have improved sensitivity, specificity, and feasibility of ctDNA detection enabling innovative clinical applications. Besides its potential use as a diagnostic biomarker and the detection of recurrence or minimal residual disease, the most widespread application of the so-called liquid biopsy is real-time monitoring of treatment response and tumor evolution. Since tissue biopsies provide just a static snapshot of the tumor at the time of biopsy and do not ...
Source: Memo - Magazine of European Medical Oncology - July 2, 2015 Category: Cancer & Oncology Source Type: research

Role of FDG-PET/CT in staging and first-line treatment of Hodgkin and aggressive B-cell lymphomas
Abstract Positron emission tomography with integrated computed tomography (PET/CT) is increasingly used for the initial staging, final or even interim (mid-treatment) response assessment in malignant lymphomas. Extensive clinical experience has been gained with Hodgkin lymphoma (HL) and aggressive B-cell non-Hodgkin lymphomas, including diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMLBCL) and other subtypes, which are the subject of the present review. The use of PET/CT is now considered mandatory for baseline staging in these entities, providing more accurate information and o...
Source: Memo - Magazine of European Medical Oncology - June 16, 2015 Category: Cancer & Oncology Source Type: research

Lung cancer in Bulgaria ‒ diagnosis, treatment, and factors affecting survival
Abstract Background In Bulgaria, lung cancer incidence and mortality rates are rising in both men and women. The study aims to present a picture of lung cancer diagnosis and treatment process and to identify factors affecting survival in advanced lung cancer patients (LCP) treated with systemic therapy. Patients and methods Data from LCP admitted at the Medical Oncology Department were retrospectively collected from electronic and hard-paper database for a 10-year period (January 2005–2015). The test for frequencies was used to describe parameters....
Source: Memo - Magazine of European Medical Oncology - June 9, 2015 Category: Cancer & Oncology Source Type: research

The role of positron emission tomography in breast cancer: a short review
Abstract Positron emission tomography (PET) provides information about abnormal metabolic features associated with cancer, and its role in breast cancer has been widely investigated. In the past several years, combined imaging systems, such as PET/CT and PET/MRI, and dedicated breast PET devices, such as PEM and MAMMI-PET, have been developed and implemented. These new techniques have become an effective oncologic tool for staging, re-staging, monitoring response to treatment, and estimation of the long-term prognosis. The aim of this review is to summarize the established and emerging PET imaging techniques and t...
Source: Memo - Magazine of European Medical Oncology - June 9, 2015 Category: Cancer & Oncology Source Type: research

PET/CT in management of oncologic patients
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - June 9, 2015 Category: Cancer & Oncology Source Type: research

The relevance of positron emission tomography response in non-small cell lung cancer
Conclusions In addition to the structural information provided by CT, the metabolic information from PET during or following treatment for NSCLC is increasingly valuable in clinical decision making. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - June 2, 2015 Category: Cancer & Oncology Source Type: research